

ASX RELEASE

Johns Hopkins Present Positive Study Results For Sienna's hTERT Test

- 500-patient study confirms clinical utility of hTERT testing as an adjunct to urine cytology
- Study results were presented by Johns Hopkins at USCAP meeting in Vancouver

Melbourne, Australia, 22 March 2018: [Sienna Cancer Diagnostics Ltd \(ASX:SDX\)](#), a medical technology company developing and commercialising innovative cancer-related tests, is pleased to announce that renowned research institute, Johns Hopkins University School of Medicine, has today presented the results of its study using Sienna's in-vitro diagnostic (IVD) hTERT test at the United States and Canadian Academy of Pathology (USCAP) 2018 Annual Meeting.

The 500-patient bladder cancer study confirmed the clinical utility of the test as an adjunct to urine cytology. The results demonstrated an increase in sensitivity when using the hTERT test in conjunction with cytology. The sensitivity of standard urine cytology alone was 29.2%, whereas cytology combined with hTERT increased the sensitivity to 50.8%, while maintaining a specificity of 89.2%. As a result, the study concluded that hTERT testing may help to identify patients with increased likelihood of High Grade Urothelial Carcinoma (HGUC), who may otherwise be missed by standard screening alone. Additionally, negative hTERT staining was shown to be associated with a decreased risk of HGUC compared to cytology alone.

The USCAP Annual Meeting is a premier event for pathologists drawing over 5,000 attendees from almost 90 countries. This year's conference is being held in Vancouver, Canada from March 17-23, 2018.

Sienna's CEO Matthew Hoskin commented: "We are delighted with the results of the study, demonstrating that our hTERT test provides valuable additional information to physicians. Having the results presented at such a prestigious gathering of pathologists will provide the hTERT test great exposure to laboratories who may ultimately offer it as part of their testing menu."

The results of the study were presented by Professor Christopher VandenBussche, associate director of cytopathology and assistant professor of pathology, and Dr Morgan Cowan, resident pathologist, both of the Johns Hopkins University School of Medicine.

In a video release, Sienna's CEO Matthew Hoskin discusses the positive findings of the clinical study investigating the use of the hTERT test as an adjunct to urine cytology for the investigation of bladder cancer. He also delves into the significance of the trial's findings for the Company, the significant market opportunity and commercialisation progress made to date.

To view the video, click here: <http://bit.ly/2pplw4T>

To view the study presentation, click here: <http://bit.ly/2IFpq1B>

- ENDS -

A decorative graphic on the right side of the page consisting of two overlapping circles, one teal and one red, with a small teal dot below them.



For further information, please contact:

Matthew Hoskin, CEO
Sienna Cancer Diagnostics
mhoskin@siennadiagnostics.com.au
+61 3 8288 2141

Scott Newstead
WE Buchan
snewstead@we-buchan.com
+61 3 8866 1218

About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd. is an Australian medical technology company, with operations in the United States, Europe and Australia. Sienna's strengths lie in identifying novel technologies then developing and commercialising them to satisfy an unmet clinical / market need. The Company has demonstrated the utility of its product with the help of its global clinical partners. Sienna's primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009. Telomerase is well recognised as a remarkable biomarker used by 85% of cancers to enable immortal cell replication.

The FDA listing of Sienna's first IVD in the United States, and CE marking / IVD registration in Europe and Australia, means the SCD-A7 reagent can be used for clinical diagnostic purposes by pathology laboratories. Clinical pathology laboratories in those regions may now purchase SCD-A7 for use as an in vitro diagnostic test for the presence of hTERT, a component of telomerase. Sienna has made available to pathology laboratories a world-first telomerase-based assay for use on human clinical specimens.

Forward Looking Statements

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

